FDA Webview

Free FDA Notices

Panel Meets on BioMarin NDA for Duchenne Muscular Dystrophy


Federal Register Notice: FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will meet 11/24, from 8 a.m. to 5:30 p.m. at FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The committee will discuss a BioMarin NDA for drisapersen solution for injection for treating patients with Duchenne muscular dystrophy with mutations in the dystrophin gene that are amenable to treatment with exon 51 skipping as determined by genetic testing. Contact Philip Bautista, (301) 796-9001. To view this notice, click here.